The Motley Fool Discussion Boards

Previous Page

Stocks C / Celera


Subject:  Re: CRA News from Washington Post Date:  3/6/2000  9:40 AM
Author:  ChasPiette Number:  6400 of 36502

the conflict:

[Francis Collins is director of the National Human Genome Research Institute and principal author of the letter]

In the letter, Collins said a prime issue was Celera's desire for restrictions on commercial use of the genome database. Celera is spending hundreds of millions of dollars on gene research and has become a Wall Street darling because of its perceived lead over other biotech companies.

Venter said his company supports the goal of completing the gene map rapidly but is concerned that research it paid for will be available for other companies to repackage and sell.